OncoMatch/Clinical Trials/NCT06195709
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Is NCT06195709 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Endocrine therapy and Endocrine therapy combined with the local treatment of FES-negative lesions for breast carcinoma.
Treatment: Endocrine therapy · Endocrine therapy combined with the local treatment of FES-negative lesions · Chemotherapy — Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER-positive, ≥10%) (≥10%)
Estrogen Receptor (ER)-positive (≥10%)
Required: HER2 (ERBB2) negative
HER2-negative (ASCO/College of American Pathologists guidelines)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: aromatase inhibitor — first line, metastatic
disease has progressed on first line endocrine therapy with aromatase inhibitor
Must have received: CDK4/6 inhibitor — first line, metastatic
disease has progressed on first line endocrine therapy with...CDK4/6 inhibitor
Cannot have received: chemotherapy
One or more prior line of chemotherapy in the metastatic setting [excluded]
Cannot have received: systemic treatment (other than first line aromatase inhibitor and CDK4/6 inhibitor)
Any other systemic treatment given at metastatic disease than the first line therapy with aromatase inhibitor and CDK4/6 inhibitor [excluded]
Cannot have received: estrogen receptor degrader (fulvestrant, oral SERDs, PROTAC)
Prior exposure to any authorized or experimental agent degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify